EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)

Hai-Dong Zhu, Xiao Li, Jun-Hui Sun, Xu Zhu, Zhao-Yu Liu, Hai-Liang Li, Jian Lu, Zhi-Ping Yan, Guo-Liang Shao, Xiao-Feng He, Min Chao, Li-Gong Lu und 4 weitere

CardioVascular and Interventional Radiology · 2024

DOI: 10.1007/s00270-024-03666-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2024. Verfasst von Hai-Dong Zhu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Ima…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

While the role of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) is established, questions regarding appropriate bead size for use in patients remain. This trial evaluated the effectiveness and safety of DEB-TACE using small-size (≤ 100 μm) microspheres loaded with epirubicin. Materials and Methods This prospective, single-arm, multicenter study enrolled patients diagnosed with HCC who underwent DEB-TACE using 40 (range, 30–50), 75 (range, 60–90), or 100 (range, 75–125) μm epirubicin-loaded microspheres (TANDEM microspheres, Varian Medical). Bead size was at the discretion of treating physicians and based on tumor size and/or vascular structure. The primary outcome measure was 6-month objective response rate (ORR). Secondary outcome measures were 30-day and 3-month ORR, time to tumor progression and extrahepatic spread, proportion of progression-free survival and overall survival (OS) at one year, and incidence of treatment-associated adverse events.

Results

Data from 108 patients from ten centers was analyzed. Six-month ORR was 73.3 and 71.3% based on European association for the study of the liver (EASL) and modified response evaluation criteria in solid tumors (mRECIST) criteria, respectively. Thirty-day ORR was 79.6% for both EASL and mRECIST criteria with 3-month ORR being 80.0 and 81.0%, respectively, for each criteria. One-year PPF and OS rate were 60.3 and 94.3%. There was a total of 30 SAEs reported to be likely to definitely associated with microsphere ( n = 9), epirubicin ( n = 9), or procedure ( n = 12) with none resulting in death.

Conclusion

DEB-TACE using epirubicin-loaded small-sized (≤ 100 μm) microspheres demonstrates promising local tumor control and acceptable safety in patients with HCC. Trial Registration Clinicaltrials.gov NCT03113955; registered April 14, 2017. Trial Registration Clinicaltrials.gov NCT03113955; registered April 14, 2017. Level of evidence 2, Prospective, Non-randomized, Single-arm, study. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticHumansEpirubicinMicrospheresProspective StudiesTreatment OutcomeDoxorubicinRetrospective Studies

Stichwörter der Autor:innen

EpirubicinHepatocellular carcinomaTANDEM microspheresTransarterial chemoembolization

Substanzen

EpirubicinDoxorubicin

Autor:innen und Institutionen

  • Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine…
  • Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing, China.
  • Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Zitieren

APA

Zhu, H. D., Li, X., Sun, J. H., Zhu, X., Liu, Z. Y., Li, H. L., Lu, J., Yan, Z. P., Shao, G. L., He, X. F., Chao, M., Lu, L. G., Zhong, B. Y., Li, R., Zhang, Q., & Teng, G. J. (2024). Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial). CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-024-03666-4

Vancouver

Zhu HD, Li X, Sun JH, Zhu X, Liu ZY, Li HL, et al. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial). CardioVascular and Interventional Radiology. 2024. doi:10.1007/s00270-024-03666-4

BibTeX
@article{Zhu2024,
  author = {Zhu, Hai-Dong and Li, Xiao and Sun, Jun-Hui and Zhu, Xu and Liu, Zhao-Yu and Li, Hai-Liang and Lu, Jian and Yan, Zhi-Ping and Shao, Guo-Liang and He, Xiao-Feng and Chao, Min and Lu, Li-Gong and Zhong, Bin-Yan and Li, Rui and Zhang, Qi and Teng, Gao-Jun},
  title = {Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)},
  journal = {CardioVascular and Interventional Radiology},
  year = {2024},
  doi = {10.1007/s00270-024-03666-4}
}
Kostenlos starten →